Vertex Pharmaceuticals Inc (VRTX) 118.55 $VRTX
Watch for Vertex Pharmaceuticals to Potentially Pullback After Gaining 3.05% Yesterday
Comtex SmarTrend(R) - Thu Dec 11, 4:02PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $117.85 to a high of $122.26. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $121.65 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 118.55 (-2.23)
After Yesterday's Rally of 3.05% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Dec 11, 4:01PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $117.85 to a high of $122.26. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $121.65 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 118.55 (-2.23)
Why Gilead Sciences and AbbVie Care About This Tiny Company
Todd Campbell, The Motley Fool - Motley Fool - Thu Dec 11, 9:18AM CST
Source: Gilead Sciences via Google Maps. Investors are focusing on AbbVie 's hepatitis C drug and its potential impact on Gilead Sciences ' hepatitis C market share if it wins FDA approval later this month. However, they might also want to keep...
VRTX: 118.55 (-2.23), GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), ABBV: 65.27 (-1.76)
Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 10, 2:10PM CST
Yet another acquisition agreement was announced even as the biotech sector was busy with showcasing data at ASH.
BLUE: 91.28 (+5.16), BIIB: 344.49 (+2.16), VRTX: 118.55 (-2.23), CBST: 96.31 (+0.04), INCY: 74.65 (-1.27), AMGN: 164.53 (-1.55), ARRY: 4.86 (-0.04)
MassMutual Announces the Election of Three Members to its Board of Directors
PR Newswire - Wed Dec 10, 11:00AM CST
Massachusetts Mutual Life Insurance Company (MassMutual) announced today it has elected three new members to its Board of Directors: Isabella D. (Bella) Goren, former Chief Financial Officer of American Airlines, Inc. and AMR Corporation; Mark T. Bertolini, Chairman, Chief Executive Officer and President of Aetna Inc., and Jeffrey M. Leiden, M.D., Ph.D., Chairman, President and CEO of Vertex Pharmaceuticals Incorporated. With the three additions, MassMutual will have 15 Board of Director members.
VRTX: 118.55 (-2.23), AET: 87.30 (-0.82)
Stock Market News for December 10, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 9:10AM CST
Benchmarks ended Tuesday’s trading session on a mixed note as investors remained concerned about the global economy and political turmoil in Greece
KMI: 39.17 (-0.71), BIIB: 344.49 (+2.16), VRTX: 118.55 (-2.23), DAL: 47.68 (-0.65), SLB: 80.00 (-3.01), ORCL: 39.95 (-0.81), UAL: 64.10 (-1.70), CELG: 114.49 (-2.25), SAVE: 68.12 (-0.88), EOG: 86.37 (-0.49), GOOGL: 521.51 (-10.60), CVX: 102.38 (-2.53), OXY: 74.22 (-0.86), AAPL: 109.73 (-1.89)
Stocks Are Dragged Lower as Oil Prices Plunge to 5-Year Low
at The Street - Mon Dec 08, 3:24PM CST
Oil prices were a sinking ship on Monday, capsizing energy stocks and almost everything else caught in their wake.
TSLA: 207.00 (-1.88), VRTX: 118.55 (-2.23), XOM: 86.60 (-2.60), COP: 62.45 (-1.16), SPWR: 23.06 (-0.41), CELG: 114.49 (-2.25), NFLX: 334.48 (-0.15), FSLR: 42.12 (-0.92), CBST: 96.31 (+0.04), GILD: 104.13 (-0.18), TOT: 50.12 (-1.10), MRK: 57.72 (-1.62), BP: 36.24 (-1.09), CVX: 102.38 (-2.53), REGN: 416.44 (-7.91), XLE: 74.02 (-1.40)
Stocks Recover From Session Lows Though Oil Prices Continue to Hurt
at The Street - Mon Dec 08, 2:30PM CST
Plunging crude oil prices and a selloff in energy stocks are weighing on benchmark indices again on Monday, limiting potential gains spurred by a rally among pharmaceuticals.
TSLA: 207.00 (-1.88), VRTX: 118.55 (-2.23), XOM: 86.60 (-2.60), COP: 62.45 (-1.16), SPWR: 23.06 (-0.41), INFY: 31.27 (-0.38), CELG: 114.49 (-2.25), NFLX: 334.48 (-0.15), FSLR: 42.12 (-0.92), RIG: 16.47 (-0.55), CBST: 96.31 (+0.04), GILD: 104.13 (-0.18), MRK: 57.72 (-1.62), EOG: 86.37 (-0.49), MCD: 90.62 (-0.35), CVX: 102.38 (-2.53), OXY: 74.22 (-0.86), REGN: 416.44 (-7.91), YUM: 72.85 (+0.83), XLE: 74.02 (-1.40)
Stocks Near Flatline as Rally in Pharmaceuticals Overshadows Energy Selloff
at The Street - Mon Dec 08, 10:04AM CST
Stocks trade flat as a rally in pharmaceuticals trumps a selloff in oil-related companies and plunging crude prices.
VRTX: 118.55 (-2.23), COP: 62.45 (-1.16), INFY: 31.27 (-0.38), CELG: 114.49 (-2.25), CBST: 96.31 (+0.04), EBAY: 55.77 (-1.01), RIG: 16.47 (-0.55), GILD: 104.13 (-0.18), MRK: 57.72 (-1.62), EOG: 86.37 (-0.49), MCD: 90.62 (-0.35), OXY: 74.22 (-0.86), REGN: 416.44 (-7.91), YUM: 72.85 (+0.83)
Time to Buy This Dip in Gilead Sciences, Inc. Stock?
George Budwell, The Motley Fool - Motley Fool - Mon Dec 08, 7:07AM CST
The past month hasn't been kind to shareholders of Gilead Sciences . After the stock reached an all-time high of $116.83 in November, shares have now fallen over 10% in roughly a three-week span. What's more, investors and hedge funds alike have...
JNJ: 104.43 (-2.29), VRTX: 118.55 (-2.23), GILD: 104.13 (-0.18), MRK: 57.72 (-1.62), ABBV: 65.27 (-1.76)
Vertex Pharmaceuticals Up 23.0% Since SmarTrend Uptrend Call (VRTX)
Comtex SmarTrend(R) - Fri Dec 05, 4:54PM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on September 18th, 2014 at $95.87. In approximately 3 months, Vertex Pharmaceuticals has returned 23.03% as of today's recent price of $117.95.
VRTX: 118.55 (-2.23)
Biotech Stock Roundup: Avanir to be Acquired by Japanese Firm, Biogen Scores in Alzheimer's Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 03, 9:51AM CST
Although it was a relatively uneventful week, mergers and acquisitions show no signs of slowing down in the biotech sector.
BIIB: 344.49 (+2.16), AVNR: 16.95 (-0.02), VRTX: 118.55 (-2.23), INCY: 74.65 (-1.27), ALXN: 186.90 (-4.72), PBYI: 196.34 (-7.66), REGN: 416.44 (-7.91)
Migraine - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/xq8n9b/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Migraine - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ache Laboratorios Farmaceuticos - Alder Biopharmaceuticals - Allergan - Amgen - Astellas Pharma - Avanir Pharmaceuticals - BioDelivery Sciences - Biofrontera - Bristol-Myers Squibb - D-Pharm - Eli Lilly and Company - Heptares Therapeutics - Impax Laboratories - IntelGenx - Istituto Italiano di Tecnologia - Medestea Research & Production - Merck & Co - Nektar Therapeutics - Northern Light Pharmaceuticals - Paladin Labs - Pfizer - Pozen - Proreo Pharma - Questcor Pharmaceuticals - Revance Therapeutics - TheraJect - Transcept Pharmaceuticals - Trigemina - Vertex Pharmaceuticals Incorporated - iCeutica For more information visit http://www.researchandmarkets.com/research/xq8n9b/migraine
VRTX: 118.55 (-2.23), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), BMY: 58.75 (-0.93), NKTR: 15.31 (-0.29), AGN: 208.47 (-2.67), IPXL: 31.16 (-0.74), ALDR: 25.27 (-1.46), QCOR: 93.60 (+1.52), MRK: 57.72 (-1.62), TSPT: 1.70 (-0.04), RVNC: 17.45 (-0.23), POZN: 9.12 (-0.08)
‘Fast Money’ Recap: Can Stocks Still Rally if Oil Prices Rebound?
at The Street - Wed Dec 03, 4:00AM CST
The trading panel discussed energy stocks, biotechs and Taser.
BIIB: 344.49 (+2.16), ABT: 43.69 (-0.77), VRTX: 118.55 (-2.23), F: 14.99 (-0.29), BMRN: 91.52 (-1.38), RRGB: 73.03 (+1.64), XOP: 43.93 (-0.43), BBRY: 9.84 (-0.32), IBB: 306.10 (-3.95), CP: 176.41 (+1.71), TASR: 23.19 (unch), XLE: 74.02 (-1.40), CELG: 114.49 (-2.25)
Global Hepatitis C Clinical Trials Market Review H2 2014 Report at ReportsnReports.com
PRWeb - Tue Dec 02, 5:30PM CST
The clinical trial report "Hepatitis C Global Clinical Trials Review H2 2014" provides data on the Hepatitis C clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatitis C. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatitis C. Complete Report Available @ http://www.reportsnreports.com/reports/319733...-2014.html .
JNJ: 104.43 (-2.29), VRTX: 118.55 (-2.23), GILD: 104.13 (-0.18), GSK: 42.42 (-0.93), BMY: 58.75 (-0.93), NVS: 93.52 (-0.82)
Technical Scrutiny on Biotech Stocks - CTI BioPharma, Vertex Pharma, Progenics Pharma, iBio, and NewLink Genetics
PR Newswire - Tue Dec 02, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corporation (NASDAQ: CTIC), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), iBio Inc. (NYSE MKT: IBIO), and NewLink Genetics Corporation (NASDAQ: NLNK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, December 01, 2014, the NASDAQ Composite ended at 4,727.35, down 1.34%, the Dow Jones Industrial Average edged 0.29% lower, to finish the day at 17,776.80, and the S&P 500 closed at 2,053.44, down 0.68%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 802.07, down 0.20%, while the index has advanced 8.74% in the previous three months. Register for your complimentary reports on these five stocks at:
PGNX: 7.10 (+0.16), VRTX: 118.55 (-2.23), NLNK: 35.69 (+0.27), IBIO: 0.69 (unch), CTIC: 2.40 (+0.02)
Vertex Pharmaceuticals' 52-Week High Driven by Kalydeco - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 4:00PM CST
Vertex Pharmaceuticals (VRTX) hit a 52-week high of $120.91 during the trading session on Nov 28.
CYTK: 4.78 (-0.06), BIIB: 344.49 (+2.16), VRTX: 118.55 (-2.23), AFFX: 8.94 (-0.36)
25.0% Return Seen to Date on SmarTrend Vertex Pharmaceuticals Call (VRTX)
Comtex SmarTrend(R) - Fri Nov 28, 11:07AM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on September 18th, 2014 at $95.87. In approximately 2 months, Vertex Pharmaceuticals has returned 25.03% as of today's recent price of $119.87.
VRTX: 118.55 (-2.23)
Stock Market News for November 28, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 9:10AM CST
Benchmarks settled in the green on Wednesday due to gains in technology and telecom stocks
VRTX: 118.55 (-2.23), FB: 77.83 (+0.10), XOM: 86.60 (-2.60), AMGN: 164.53 (-1.55), HPQ: 38.01 (-0.46), SLB: 80.00 (-3.01), CELG: 114.49 (-2.25), YHOO: 50.24 (+0.30), T: 32.16 (-0.55), ADI: 55.92 (-0.33), CVX: 102.38 (-2.53), MSFT: 46.95 (-0.22), AAPL: 109.73 (-1.89), VZ: 45.58 (-0.78), REGN: 416.44 (-7.91)
Watch for Vertex Pharmaceuticals to Potentially Pullback After Gaining 3.05% Yesterday
Comtex SmarTrend(R) - Thu Dec 11, 4:02PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $117.85 to a high of $122.26. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $121.65 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 118.55 (-2.23)
After Yesterday's Rally of 3.05% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Dec 11, 4:01PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $117.85 to a high of $122.26. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $121.65 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 118.55 (-2.23)
Why Gilead Sciences and AbbVie Care About This Tiny Company
Todd Campbell, The Motley Fool - Motley Fool - Thu Dec 11, 9:18AM CST
Source: Gilead Sciences via Google Maps. Investors are focusing on AbbVie 's hepatitis C drug and its potential impact on Gilead Sciences ' hepatitis C market share if it wins FDA approval later this month. However, they might also want to keep...
VRTX: 118.55 (-2.23), GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), ABBV: 65.27 (-1.76)
Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 10, 2:10PM CST
Yet another acquisition agreement was announced even as the biotech sector was busy with showcasing data at ASH.
BLUE: 91.28 (+5.16), BIIB: 344.49 (+2.16), VRTX: 118.55 (-2.23), CBST: 96.31 (+0.04), INCY: 74.65 (-1.27), AMGN: 164.53 (-1.55), ARRY: 4.86 (-0.04)
MassMutual Announces the Election of Three Members to its Board of Directors
PR Newswire - Wed Dec 10, 11:00AM CST
Massachusetts Mutual Life Insurance Company (MassMutual) announced today it has elected three new members to its Board of Directors: Isabella D. (Bella) Goren, former Chief Financial Officer of American Airlines, Inc. and AMR Corporation; Mark T. Bertolini, Chairman, Chief Executive Officer and President of Aetna Inc., and Jeffrey M. Leiden, M.D., Ph.D., Chairman, President and CEO of Vertex Pharmaceuticals Incorporated. With the three additions, MassMutual will have 15 Board of Director members.
VRTX: 118.55 (-2.23), AET: 87.30 (-0.82)
Stock Market News for December 10, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 9:10AM CST
Benchmarks ended Tuesday’s trading session on a mixed note as investors remained concerned about the global economy and political turmoil in Greece
KMI: 39.17 (-0.71), BIIB: 344.49 (+2.16), VRTX: 118.55 (-2.23), DAL: 47.68 (-0.65), SLB: 80.00 (-3.01), ORCL: 39.95 (-0.81), UAL: 64.10 (-1.70), CELG: 114.49 (-2.25), SAVE: 68.12 (-0.88), EOG: 86.37 (-0.49), GOOGL: 521.51 (-10.60), CVX: 102.38 (-2.53), OXY: 74.22 (-0.86), AAPL: 109.73 (-1.89)
Stocks Are Dragged Lower as Oil Prices Plunge to 5-Year Low
at The Street - Mon Dec 08, 3:24PM CST
Oil prices were a sinking ship on Monday, capsizing energy stocks and almost everything else caught in their wake.
TSLA: 207.00 (-1.88), VRTX: 118.55 (-2.23), XOM: 86.60 (-2.60), COP: 62.45 (-1.16), SPWR: 23.06 (-0.41), CELG: 114.49 (-2.25), NFLX: 334.48 (-0.15), FSLR: 42.12 (-0.92), CBST: 96.31 (+0.04), GILD: 104.13 (-0.18), TOT: 50.12 (-1.10), MRK: 57.72 (-1.62), BP: 36.24 (-1.09), CVX: 102.38 (-2.53), REGN: 416.44 (-7.91), XLE: 74.02 (-1.40)
Stocks Recover From Session Lows Though Oil Prices Continue to Hurt
at The Street - Mon Dec 08, 2:30PM CST
Plunging crude oil prices and a selloff in energy stocks are weighing on benchmark indices again on Monday, limiting potential gains spurred by a rally among pharmaceuticals.
TSLA: 207.00 (-1.88), VRTX: 118.55 (-2.23), XOM: 86.60 (-2.60), COP: 62.45 (-1.16), SPWR: 23.06 (-0.41), INFY: 31.27 (-0.38), CELG: 114.49 (-2.25), NFLX: 334.48 (-0.15), FSLR: 42.12 (-0.92), RIG: 16.47 (-0.55), CBST: 96.31 (+0.04), GILD: 104.13 (-0.18), MRK: 57.72 (-1.62), EOG: 86.37 (-0.49), MCD: 90.62 (-0.35), CVX: 102.38 (-2.53), OXY: 74.22 (-0.86), REGN: 416.44 (-7.91), YUM: 72.85 (+0.83), XLE: 74.02 (-1.40)
Stocks Near Flatline as Rally in Pharmaceuticals Overshadows Energy Selloff
at The Street - Mon Dec 08, 10:04AM CST
Stocks trade flat as a rally in pharmaceuticals trumps a selloff in oil-related companies and plunging crude prices.
VRTX: 118.55 (-2.23), COP: 62.45 (-1.16), INFY: 31.27 (-0.38), CELG: 114.49 (-2.25), CBST: 96.31 (+0.04), EBAY: 55.77 (-1.01), RIG: 16.47 (-0.55), GILD: 104.13 (-0.18), MRK: 57.72 (-1.62), EOG: 86.37 (-0.49), MCD: 90.62 (-0.35), OXY: 74.22 (-0.86), REGN: 416.44 (-7.91), YUM: 72.85 (+0.83)
Time to Buy This Dip in Gilead Sciences, Inc. Stock?
George Budwell, The Motley Fool - Motley Fool - Mon Dec 08, 7:07AM CST
The past month hasn't been kind to shareholders of Gilead Sciences . After the stock reached an all-time high of $116.83 in November, shares have now fallen over 10% in roughly a three-week span. What's more, investors and hedge funds alike have...
JNJ: 104.43 (-2.29), VRTX: 118.55 (-2.23), GILD: 104.13 (-0.18), MRK: 57.72 (-1.62), ABBV: 65.27 (-1.76)
Vertex Pharmaceuticals Up 23.0% Since SmarTrend Uptrend Call (VRTX)
Comtex SmarTrend(R) - Fri Dec 05, 4:54PM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on September 18th, 2014 at $95.87. In approximately 3 months, Vertex Pharmaceuticals has returned 23.03% as of today's recent price of $117.95.
VRTX: 118.55 (-2.23)
Biotech Stock Roundup: Avanir to be Acquired by Japanese Firm, Biogen Scores in Alzheimer's Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 03, 9:51AM CST
Although it was a relatively uneventful week, mergers and acquisitions show no signs of slowing down in the biotech sector.
BIIB: 344.49 (+2.16), AVNR: 16.95 (-0.02), VRTX: 118.55 (-2.23), INCY: 74.65 (-1.27), ALXN: 186.90 (-4.72), PBYI: 196.34 (-7.66), REGN: 416.44 (-7.91)
Migraine - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/xq8n9b/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Migraine - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ache Laboratorios Farmaceuticos - Alder Biopharmaceuticals - Allergan - Amgen - Astellas Pharma - Avanir Pharmaceuticals - BioDelivery Sciences - Biofrontera - Bristol-Myers Squibb - D-Pharm - Eli Lilly and Company - Heptares Therapeutics - Impax Laboratories - IntelGenx - Istituto Italiano di Tecnologia - Medestea Research & Production - Merck & Co - Nektar Therapeutics - Northern Light Pharmaceuticals - Paladin Labs - Pfizer - Pozen - Proreo Pharma - Questcor Pharmaceuticals - Revance Therapeutics - TheraJect - Transcept Pharmaceuticals - Trigemina - Vertex Pharmaceuticals Incorporated - iCeutica For more information visit http://www.researchandmarkets.com/research/xq8n9b/migraine
VRTX: 118.55 (-2.23), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), BMY: 58.75 (-0.93), NKTR: 15.31 (-0.29), AGN: 208.47 (-2.67), IPXL: 31.16 (-0.74), ALDR: 25.27 (-1.46), QCOR: 93.60 (+1.52), MRK: 57.72 (-1.62), TSPT: 1.70 (-0.04), RVNC: 17.45 (-0.23), POZN: 9.12 (-0.08)
‘Fast Money’ Recap: Can Stocks Still Rally if Oil Prices Rebound?
at The Street - Wed Dec 03, 4:00AM CST
The trading panel discussed energy stocks, biotechs and Taser.
BIIB: 344.49 (+2.16), ABT: 43.69 (-0.77), VRTX: 118.55 (-2.23), F: 14.99 (-0.29), BMRN: 91.52 (-1.38), RRGB: 73.03 (+1.64), XOP: 43.93 (-0.43), BBRY: 9.84 (-0.32), IBB: 306.10 (-3.95), CP: 176.41 (+1.71), TASR: 23.19 (unch), XLE: 74.02 (-1.40), CELG: 114.49 (-2.25)
Global Hepatitis C Clinical Trials Market Review H2 2014 Report at ReportsnReports.com
PRWeb - Tue Dec 02, 5:30PM CST
The clinical trial report "Hepatitis C Global Clinical Trials Review H2 2014" provides data on the Hepatitis C clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatitis C. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatitis C. Complete Report Available @ http://www.reportsnreports.com/reports/319733...-2014.html .
JNJ: 104.43 (-2.29), VRTX: 118.55 (-2.23), GILD: 104.13 (-0.18), GSK: 42.42 (-0.93), BMY: 58.75 (-0.93), NVS: 93.52 (-0.82)
Technical Scrutiny on Biotech Stocks - CTI BioPharma, Vertex Pharma, Progenics Pharma, iBio, and NewLink Genetics
PR Newswire - Tue Dec 02, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corporation (NASDAQ: CTIC), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), iBio Inc. (NYSE MKT: IBIO), and NewLink Genetics Corporation (NASDAQ: NLNK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, December 01, 2014, the NASDAQ Composite ended at 4,727.35, down 1.34%, the Dow Jones Industrial Average edged 0.29% lower, to finish the day at 17,776.80, and the S&P 500 closed at 2,053.44, down 0.68%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 802.07, down 0.20%, while the index has advanced 8.74% in the previous three months. Register for your complimentary reports on these five stocks at:
PGNX: 7.10 (+0.16), VRTX: 118.55 (-2.23), NLNK: 35.69 (+0.27), IBIO: 0.69 (unch), CTIC: 2.40 (+0.02)
Vertex Pharmaceuticals' 52-Week High Driven by Kalydeco - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 4:00PM CST
Vertex Pharmaceuticals (VRTX) hit a 52-week high of $120.91 during the trading session on Nov 28.
CYTK: 4.78 (-0.06), BIIB: 344.49 (+2.16), VRTX: 118.55 (-2.23), AFFX: 8.94 (-0.36)
25.0% Return Seen to Date on SmarTrend Vertex Pharmaceuticals Call (VRTX)
Comtex SmarTrend(R) - Fri Nov 28, 11:07AM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on September 18th, 2014 at $95.87. In approximately 2 months, Vertex Pharmaceuticals has returned 25.03% as of today's recent price of $119.87.
VRTX: 118.55 (-2.23)
Stock Market News for November 28, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 9:10AM CST
Benchmarks settled in the green on Wednesday due to gains in technology and telecom stocks
VRTX: 118.55 (-2.23), FB: 77.83 (+0.10), XOM: 86.60 (-2.60), AMGN: 164.53 (-1.55), HPQ: 38.01 (-0.46), SLB: 80.00 (-3.01), CELG: 114.49 (-2.25), YHOO: 50.24 (+0.30), T: 32.16 (-0.55), ADI: 55.92 (-0.33), CVX: 102.38 (-2.53), MSFT: 46.95 (-0.22), AAPL: 109.73 (-1.89), VZ: 45.58 (-0.78), REGN: 416.44 (-7.91)
